Menu
Recruiting NCT07513727

Vitamin C for Gingival Depigmentation

No phase Interventional Gingival Hyperpigmentation Gingival Melanin Pigmentation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Topical Vitamin C ( control Arm), Vitamin C mesotherapy, Microneedling technique.
Who it may be relevant to
Registry conditions: Gingival Hyperpigmentation, Gingival Melanin Pigmentation. Basic parameters: 20 years — 40 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Clinical and Histological Evaluation of Topical Vitamin C Application Using Three Modalities in Gingival Depigmentation

Overview

The purpose of this study is to evaluate the clinical and histopathological efficacy of topical vitamin C applications using three modalities (topical gel, microneedling , and mesotherapy) in gingival depigmentation. Assessment includes clinical evaluation, CIELAB analysis via DOPI, and histopathological examination (Fontana-Masson staining).

Interventions

  • Drug Topical Vitamin C ( control Arm)
    Topical application of L-Ascorbic Acid gel (1000 mg in 5 ml distilled water with CMC and PEG), applied once daily on gingival hyperpigmented areas for 1 month.
  • Procedure Vitamin C mesotherapy
    vitamin C mesotherapy was administered by delivering intra-mucosal microinjections of L-ascorbic acid into pigmented gingival tissues at the epithelium-connective tissue junction, providing targeted delivery to melanocyte-rich layers. . The treatment will be repeated 3 times with 1 week .
  • Procedure Microneedling technique
    Gingival microneedling was performed using a Derma Pen A6 (12-needle row), with penetration depth adjusted to gingival thickness at 700 cycles/min (mode 6). Each gingival side was treated 30-40 seconds per tooth until bleeding points appeared.

Primary outcome measures

  • Dummet oral Pigmentation Index (DOPI). [Time frame: baseline to 3 months]
Secondary outcome measures (2)
  • Melanin area fraction [Time frame: baseline to 3 months]
  • Patient satisfaction [Time frame: 2 weeks , 1 month , and 3 months]

Eligibility criteria

Inclusion criteria

\- 1- Both genders aged from 20-35 years. 2- Patients clinically diagnosed with physiologic gingival melanin pigmentation in the maxillary and mandibular keratinized gingiva.

3- Patients complaining of compromised esthetics. 4- Patients should be systemically free any disease as verified by a medical history diagnostic sheet or via health questionnaire

Exclusion criteria

\- 1- Patient clinically diagnosed with periodontitis and / or manifest poor oral hygiene with high plaque and gingival indices 2- Pregnant or lactating females. 3- Patients with clinical diagnosed lesion in the area of interest primarily the gingivae encompassing the maxillary /mandibular anterior teeth e.g. pigmented lesion of intestinal polyposis syndrome, McCune-Albright syndrome and fibro-osseous lesions as florid osseous dysplasia.

4- Patient with previous treatment of gingival hyperpigmentation. 5- Patients with history of being allergic to the vitamin C. 6- Patients with any systemic disease ( e.g. Addison disease ) or drugs consumed that may cause clinical gingival hyperpigmentation 7- Patients who are active or previous smokers.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Al-Azhar University Faculty of Dentistry ( Girls ) — Cairo

Identifiers

NCT: NCT07513727 · K.Al.K-2025-01 · OMPDR-105-1t

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗